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SCHIZOPHRENIA AND PUBLIC MENTAL HEALTH
The public health impact of schizophrenia can be gau-
ged according to a number of criteria, covering: (i) fre-
quency; (ii) severity; (iii) consequences; (iv) availability
and acceptability of interventions; and (v) public con-
cern (Thornicroft & Tansella, 1999). Concerning the fir-
st three of these criteria, one of the more powerful ways
to demonstrate the broad personal and societal impacts
of an illness like schizophrenia is to show how disabling
it can be, both in absolute terms and in comparison with
other health problems. As the latest World Health Re-
port from the WHO (World Health Organisation, 2001)
makes plain, the chronic course and debilitating effects
of schizophrenia combine to create an illness which im-
poses very considerable clinical, social and economic con-
sequences on societies throughout the world, resulting
in it being a leading contributor to global and regional
levels of disability and overall disease burden (for exam-
ple, 5% of all years lived with a disability in 15-44 year
olds, and 2.8% for all ages).
From an economic perspective, this societal burden
can be couched not only in terms of a far-reaching set
of needs for formal health care provision that absorb hi-
gh levels of public expenditure, but also in other domains
of support such as housing, employment, criminal justi-
ce services and informal care (Knapp, 1997). The esti-
mated indirect annual cost of lost production in the UK,
for example, is £1.7bn, and it is the single largest disease
Indirizzo per la corrispondenza: Dr. D. Chisholm, Global
Programme on Evidence for Health Policy, World Health Organisation,
1211 Geneva (CH).
E- mail: chisholmd@who.ch
category in terms of health service expenditure, ac-
counting for 9% of in-patient health service expenditu-
re. Cost of illness studies demonstrate the absolute ma-
gnitude of costs associated with the disorder (0.5% to as
high as 3.5% of gross national health care expenditure),
the high proportion of direct costs still tied up in hospi-
tal care (often well over 50%) and the relative contribu-
tion of lost productivity and mortality to overall cost esti-
mates (approximately 50%).
THE EFFECTIVENESS AND COST-EFFECTIVE-
NESS OF SCHIZOPHRENIA TREATMENT
Moving to our fourth public health criteria, the avai-
lability and acceptability of interventions, the accumu-
lated effectiveness and cost-effectiveness evidence re-
garding treatment responses to the burden of schizoph-
renia provides encouraging but hardly remarkable indi-
cations. As a first step, two Cochrane systematic reviews
have clearly shown the superiority but limited accepta-
bility of older anti-psychotic drugs such as chlorproma-
zine or haloperidol over placebo (Thornley et al, 2001;
Joy et al, 2001), while the arrival of so-called atypical
antipsychotics has made available to patients and clini-
cians a set of pharmacological treatment options that are
no less efficacious and somewhat more tolerable. There
is also now an accumulation of evidence that clearly de-
monstrates cost-effectiveness in randomised trials (e.g,
see Essock et al, 2000; Hamilton et al, 1999; Ro-
senheck et al, 1999). The economic evidence for psy-
chosocial interventions is less prevalent - mainly because
few studies have yet been completed - but there are po-
sitive findings that point to the cost-effectiveness of fa-
mily interventions to reduce the impact of family stress
and conflict often seen in households with high expres-
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sed emotion (Xiong et al., 1994) and of a short psycho-
educational programme to improve patient adherence with
medication recommendations (Healey et al., 1998).
There are also now numerous studies pointing to the
economic consequences of different organisational ar-
rangements for providing mental health care. Until about
a decade ago, most such attention was focussed on the
development of community alternatives to long-stay in-
patient care, following the (often partly political) deci-
sions to close the old asylums. More recently, however,
attention has turned to the precise forms of community
care that can deliver the best patient, family and social
outcomes. The evidence is perhaps less straightforward
than might previously have been thought, and the effec-
tiveness and cost-effectiveness evidence less equivocal
(Burns et al., 2001), so that the search goes on across
most mental health systems for improved care arrange-
ments.
INTERNATIONAL COMPARISONS
OF SCHIZOPHRENIA CARE:
THE EPSILON STUDY
The multiplicity of care arrangements for people with
schizophrenia that have emerged in different countries,
together with the responsibility of governments and
health care agencies to ensure that resources are targe-
ted appropriately, has led to a growing interest in com-
parative studies of disease burden, both within and
between individual countries. To date, multi-national stu-
dies of schizophrenia have focused on establishing the
prevalence of the disease and assessing outcomes cross-
culturally rather than examining the relationship between
inputs, processes and outcomes.
The EPSILON {European Psychiatric Services: Inputs
Linked to Outcome Domains and Needs) study, by con-
trast, is a comparative, cross-sectional study of the cha-
racteristics, needs and life qualities of people with schi-
zophrenia in five European countries, the services they
receive, and the associated costs and satisfaction levels.
The aim of the economic component of the EPSILON
study was to develop and apply appropriate methods and
instrumentation for the cross-cultural measurement of ser-
vice utilisation and costs for people with schizophrenia,
which could be used subsequently to undertake compa-
rative economic analyses across a number of European
countries. The overall aims, hypotheses and methods of
the EPSILON study, and a description of the participa-
ting sites, are detailed elsewhere (Becker et al., 2000).
The two primary objectives of this study were to pro-
duce standardised versions of five instruments (see
Becker et al., 2002) in key areas of mental health servi-
ce research in five European languages, and to compa-
re, across five European centres (Amsterdam, Copenha-
gen, London, Santander and Verona), social and clinical
data for people with schizophrenia, the mental health ca-
re they receive and the associated costs.
A prevalence sample of people with schizophrenia in
contact with mental health services in the three months
preceding the start of the study was taken in each site,
identified from either case registers (Copenhagen and Ve-
rona) or the caseloads of specialist services (elsewhere).
All sites had broadly sectorised mental health care deli-
very. Cases identified were diagnosed using the Item
Group Checklist (IGC) of the Schedule for Clinical As-
sessment in Neuropsychiatry. Only patients aged 18-65
with an ICD-10 F20 research diagnosis were included.
Individuals resident in prison, secure residential servi-
ces or hostels for long-term patients, and hospital inpa-
tients continuously resident for more than one year, we-
re excluded in order to concentrate on those in current
'active' care by specialist mental health teams. Local ser-
vices were described using the European Service Map-
ping Schedule (Johnson et al, 2000).
METHODS FOR ECONOMIC ANALYSIS
IN MULTI-NATIONAL MENTAL HEALTH STUDIES
In the multi-national EPSILON study, information was
obtained on each patient's service utilisation, employment
status, income level and living situation. Subsequent to
a review of alternative methods of data capture (inclu-
ding psychiatric case registers and health information sy-
stems), a structured interviewer-administered instrument
was developed. The instrument is a substantial develop-
ment of the Client Service Receipt Inventory developed
some years ago (Beecham & Knapp, 1992). The CSSRI-
EU was translated into the local languages and subjec-
ted to cross-cultural validity checks via the focus grou-
ps composed of health and social care professionals, users
and carers (Chisholm et al., 2000). This process resul-
ted in modification of content and language - in parti-
cular adjustments to categories of employment, income,
housing and service provision - to achieve face validity
and semantic equivalence across sites.
For each service unit costs were calculated in each si-
te - with one or two exceptions - to cover: salaries of
staff employed in direct patient care and management;
facility operating costs (cleaning, catering, consumables,
etc.); overhead costs relating to the service (personnel,
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finance, etc.); and capital costs (buildings and equipment).
Unit costs were converted into UK pounds using 'pur-
chasing power parities' (PPPs), which are the rates of
currency conversion which eliminate price level diffe-
rences between countries and which are routinely cal-
culated by the OECD in collaboration with the Statisti-
cal Office of the European Communities.
HEALTH ECONOMIC RESULTS
FROM THE EPSILON STUDY
Full results are presented elsewhere (Knapp et al., in
press), but one of the most important findings was of wi-
despread and considerable differences between the par-
ticipating sites both in the proportions of patients in con-
tact with services and in the absolute levels of service
utilisation. These can be seen from figure 1, which gi-
ves the proportional contributions to total service costs
by site. By attaching costs to service utilisation patterns,
resources employed across a number of sectors are con-
verted into the common metric of money, which useful-
ly highlights the considerable financial implications of
providing care for people with schizophrenia. Our esti-
mates of total average costs of care, ranging widely
between £1,558 per annum in Santander to £9,934 in Co-
penhagen, are broadly in line with previous local esti-
mates of annual mean cost for this client group (Boniz-
zato etal, 2000; Evers & Ament, 1995; Haro etai, 1998;
McCrone et al., 1998). It is worth emphasising, howe-
ver, that behind the estimated total annual cost per pa-
tient for the whole sample of 404 subjects (£5,038), the-
re is not only a six-fold variation between sites but also
a much larger variation within sites.
The observed cost variations have been explored at
the individual level through multivariate cost analyses,
which provide an empirical baseline from which to exa-
mine differences within and across sites in the patterns
of relationship in costs and their associations with indi-
vidual needs, psychopathology, socio-demographic fea-
tures, service history and service satisfaction. Site-spe-
cific analyses demonstrated a number of (intuitively lo-
gical) associations between costs and higher needs, grea-
ter symptom severity and longer psychiatric history, but
not for quality of life or service satisfaction; these asso-
ciations were broadly mirrored in pooled analyses, with
the addition of the hypothesised association with servi-
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Figure 1- Direct service costs of schizophrenia (GBP, PPP) in five European countries.
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ce satisfaction. We also found key site-level characteri-
stics to have an important bearing on cost variations. In
particular, there is a link between rates of service uptake
and local levels of service availability, support for whi-
ch is given by a post hoc comparison between total ser-
vice costs and available inpatient hospital and residen-
tial care places (see figure 2). For example, the fourfold
difference in residential places between Copenhagen
(381 per 100,000 population over 18 years) and Santan-
der (93 places) closely mirrors the difference in service
costs for these sites. In other words, supply-side factors
might heavily influence the utilisation and hence costs
of care packages.
In addition to the description of the multifaceted co-
sts of care for people with schizophrenia and the eluci-
dation of key patient- and site-level influences on these
costs, the EPSILON data set also provides a basis for
examining the relative magnitude of these costs seen from
the wider perspective of the health care sector as a who-
le. Figure 3 illustrates the mean service costs associated
with schizophrenia care in the five EPSILON sites (on
this occasion measured in international dollars), relati-
ve to per capita health expenditure in the five respecti-
ve countries. Annual costs per case exceed per capita
health care expenditures by 300-900% across the five
centres. In the Danish, English, and Italian sites, these
costs are more than 800% of the average per capita pu-
blic health care expenditure in these countries. Costs of
care in the Dutch site were 433% and in the Spanish si-
te 282%, most likely owing to the very low admission
rate in the former sampled population and the relatively
modest set of public health care services available to the
latter sampled population at the time that the EPSILON
study was carried out. Summarising and comparing da-
ta in this way is certainly subject to a number of limita-
tions and should accordingly be treated with caution -
for example, sampled populations or localities may not
be representative of their respective clinical populations
or countries - but nonetheless do seem to show that the-
re is a clear and marked excess economic burden asso-
ciated with schizophrenia in Europe.
IMPLICATIONS FOR MENTAL HEALTH POLICY
AND RESEARCH IN EUROPE
Schizophrenia has major public health implications,
not only in terms of the devastating consequences of il-
lness on quality of life, but also in terms of excess mor-
tality from natural as well as unnatural causes (Harris &
Barraclough, 1998). Many people with schizophrenia not
only suffer dreadful symptoms and debilitating treatment
side-effects, but also stigmatisation, low chances of em-
ployment, social exclusion and (all too often) social and
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Figure 2 - Schizophrenia care: cost and places.
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economic impoverishment. Social isolation and home-
lessness are also common, and family strain is a widely
reported consequence of the illness. Not surprisingly, the-
refore, health system decision makers are energetically
searching for interventions that can improve health and
quality of life. But, in this search, they also need to be
aware of their resource constraints. It is not enough to
be pursuing effectiveness, fundamental though that is to
any health system. It is also necessary to address cost-
effectiveness: to seek to achieve health and quality of li-
fe improvements in affordable and efficient ways. And
a starting point for any cost-effectiveness discussion or
enquiry is an understanding of the economic conse-
quences of the condition under investigation.
The economic impact of schizophrenia on health sy-
stems and more widely depends on the structure of tho-
se systems and, of course, on a country's overall com-
mitment to treatment and support. But although the eco-
nomic impact of schizophrenia will vary from country
to country, it is clear that some pervasive patterns emer-
ge from the available evidence. The EPSILON study -
being unusual in its purposive collection of equivalent
data from five sites across Europe - contributes to that
evidence. One immediate conclusion to draw from the
EPSILON study is that the health system context has qui-
te a bearing on the economic consequences of a chronic
illness. Another is that the aggregate cost of schizoph-
renia is high. Third, and despite the fact that all five coun-
tries in the EPSILON study have reduced their numbers
of in-patient psychiatric beds quite noticeably over re-
cent decades, hospitalisation remains a major cost fac-
tor. However, and fourth, the extent of the transition from
a hospital-dominated to a community-centred mental
health system is visible from the evidence on the num-
ber and range of other services used by patients across
most sites. Social services and housing agencies (posi-
tively) and the criminal justice system (negatively) are
becoming increasingly important in the planning of so-
cietal responses to long-term mental health problems.
Fifth, beyond these 'formal' service patterns are the less
well measured but at least equally important 'informal'
supports on which so many people with schizophrenia
rely. Families are often the first line carers for schi-
zophrenia patients, and although their inputs were not
costed in EPSILON, other parts of the research programme
demonstrate the importance of this often under-recogni-
sed source of support.
The EPSILON study has provided many insights in-
to schizophrenia care, as seen through the lens of a mul-
ti-country study. Such multi-national cost comparisons,
however, need to be understood in terms of, and take in-
to account, differential levels of service access and avai-
lability, since these supply-side factors clearly have a po-
tentially important influence on the interpretation of re-
source utilisation and cost findings at the level of sam-
pled populations. Where it is not possible to do so - be-
cause the relevant data have not been collected, or be-
cause there are not statistical techniques to control ade-
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Figure 3 - Comparative cost of schizophrenia care relative to average per capita expenditures ($US PPP, 1997/98).
Epidemiologia e Psichiatria Sociale, 11, 1, 2002
16
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1121189X00010095
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 15:56:30, subject to the Cambridge Core terms of use, available at
The economics of schizophrenia care in Europe: the EPSILON study
quately for such influences - analytical findings from
pooled, multi-national data can still reveal the extent of
individual or inter-site differences but cannot provide a
full, integrated explanation of the relative contribution
that individual versus site-level factors make to these ob-
served differences. Accordingly, one priority for future
European endeavours in mental health services research
should be to work from the platform established in the
EPSILON study in order to gain a much deeper under-
standing of what our health systems can achieve - and
at what cost.
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